ArticleFrontiers in nutrition2025
Synergistic therapy for osteoporosis: a soybean osteogenic peptide-loaded fish gelatin/κ-carrageenan gel for enhanced bone regeneration.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a widespread skeletal disorder associated with reduced bone formation and increased fracture risk. Peptide-based therapeutics offer demonstrate anabolic potential for osteoporosis management but are limited by instability and rapid clearance. In this study, a dual-network hydrogel composed of fish gelatin (FG) and κ-carrageenan (κ-CG) was developed as a biocompatible carrier for a soybean-derived osteogenic peptide (SOP). The FG/κ-CG system exhibited provided mechanical integrity, hydration balance, and thermal stability, thereby enabling sustained peptide protection and controlled release. In a glucocorticoid-induced zebrafish osteoporosis model, oral administration of the SOP-loaded gel effectively restored bone mineralization to a level comparable with alendronate treatment. These findings suggest that the FG/κ-CG-SOP hydrogel provides a stable and bioactive platform for osteogenic peptide delivery and represents a promising nutritional or therapeutic approach for osteoporosis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.